REFERENCES

1. Douglas VC, Josephson SA. Delirium. Continuum (Minneap Minn). 2010;16(2): 120-134.

2. Douglas V Hessler CS, Dhaliwal G, et al. The AWOL tool: derivation and validation of a delirium prediction rule.

3. Hatta K, Kishi Y, Wada K. Preventative effects of ramelteon on delirium: a randomized placebo- controlled trial. JAMAPsychiatry. 2014;74(4):397-403.

4. Dubey D, Kothapalli N, McKeon A, et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. JNeuroimmunol. 2018;323:62-72.

5. Wijdicks EF, Varelas PN, Gronseth GS, Greer DM; American Academy of Neurology. Evidence­based guideline update. Determining brain death in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(23):1911-1918.

6. Rossetti AO, Rabinstein AA, Oddo M. Neurological prognostication of outcome in patients in coma after cardiac arrest. Lancet Neurol. 2016;15(6):597-609.

7. Sarff M, Gold JA. Alcohol withdrawal syndromes in the intensive care unit. Crit Care Med. 2010;38(9):S494-S501.

8. Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta­analysis. Neurology. 2011;77(10):1005-1012.

9. Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol. 2002;40(1):142.

10. Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl JMed. 1998;338(7):429-434.

11. Arif H, Hirsch LJ. Treatment of status epilepticus. Semin Neurol. 2008;28(3):342-354.

12. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-1120.

13. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42(10): 1255-1260.

14. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077.

15. Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol. 2011;10(11):961-968.

16. Solomon AJ. Diagnosis, differential diagnosis, and misdiagnosis of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):611-635.

17. Leurs C, Twaalfhoven H, Lissenberg-Witte B, et al. Kappa free light chains is a valid tool in the diagnostics of MS: a large multicenter study. Mult Scler. 2020;26(8):912-923.

18. Oliveira-Filho J, Silva SC, Trabuco CC, et al. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology. 2003;61(8):1047-1051.

19. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research

Interdisciplinary Working Groups. The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655-1711.

20. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. NEngl JMed. 2008;359(13):1317-1329.

21. Thomalla G, Simonsen CZ, Boutitie F, et al. WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. NEngl J Med. 2018;379(7):611-622.

22. Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council.

23. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. NEngl JMed. 2018;378(8):708-718.

24. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and Infarct. NEngl JMed. 2018;378(1):11-21.

25. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. NEngl JMed. 1991;325(7):445-453.

26. Brott TG, Hobson RWII, Howard G, et al. Stenting versus endarterectomy for treatment of carotid­artery stenosis. NEngl JMed. 2010;363(1):11-23.

27. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. J Am Med Assoc. 1995;273(18):1421-1428.

28. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke. 2004;35(10):2425-2427.

29. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure­lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041.

30. Smith SC Jr, Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol. 2014;64(6):601-612.

31. McCrory P, Meeuwisse WH, Aubry M, et al. Consensus statement on concussion in sport: the 4th International Conference on Concussion in Sport, Zurich, November 2012. J Athl Train. 2013;48(4):554-575.

32. Tolosa E, Wenning G, Poewe W The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5(1):75-86.

33. Mena MA, de Yebenes JG.

34. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7(10):939-950.

35. Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130(pt 9):2245-2257.

36. Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72(18):1548-1554.

37. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-2023.

38. Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance. Developing treatment guidelines for myasthenia gravis. Ann N YAcad Sci. 2018 1412(1):95-101.

39. Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069-1077.

40. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl JMed. 2016;375(6):511-522.

41. Boyer EW, Shannon M. The serotonin syndrome. NEngl JMed. 2005;352(11):1112-1120.

42. Brook I. Current concepts in the management of Clostridium tetani infection. Expert Rev Anti Infect Ther. 2008;6(3):327-336.